Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Theriva Biologics Inc. (TOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.25% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.90M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.83 | 52 Weeks Range 0.40 - 7.25 | Updated Date 06/29/2025 |
52 Weeks Range 0.40 - 7.25 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.71% | Return on Equity (TTM) -100.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3263527 | Price to Sales(TTM) - |
Enterprise Value -3263527 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.72 | Shares Outstanding 9059240 | Shares Floating 8173972 |
Shares Outstanding 9059240 | Shares Floating 8173972 | ||
Percent Insiders 0.11 | Percent Institutions 6.75 |
Analyst Ratings
Rating 2 | Target Price 7 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Theriva Biologics Inc.
Company Overview
History and Background
Theriva Biologics, Inc. (TOPS) is a diversified clinical-stage company committed to developing novel therapies to treat diseases where significant unmet medical needs exist. Formerly known as Synthetic Biologics, it changed its name to Theriva Biologics in September 2022 to reflect its expanded focus on novel biological therapies.
Core Business Areas
- Oncolytic Virus Platform: Developing oncolytic virus therapies for the treatment of cancer. Lead product candidate is VCN-01.
- VCN Therapy: Development of VCN platform for targeted cancer therapy, focuses on cancer that has metastisized through the Retinal pathway.
Leadership and Structure
The leadership team includes Steven A. Shallcross (CEO), Dr. Jonathan Hoyland (CSO). The company operates with a management team overseeing various functions like clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- VCN-01: An oncolytic adenovirus engineered to selectively replicate within tumor cells and promote their destruction. Currently in clinical trials. Market share is currently N/A, as it is still in clinical trials. Competitors: Oncolytic virus therapies from companies like Amgen (Imlygic).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory scrutiny. The oncolytic virus therapy market is growing due to increasing cancer prevalence and advancements in biotechnology.
Positioning
Theriva Biologics is a clinical-stage company focused on oncolytic virus therapies. Its competitive advantage lies in its VCN-01 technology and targeted approach to cancer treatment.
Total Addressable Market (TAM)
The TAM for oncolytic virus therapies is estimated to be in the billions of dollars, and it is expected to continue growing. Theriva Biologics is positioned to capture a portion of this market with its VCN-01 product candidate, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virus platform
- Targeted approach to cancer treatment
- Experienced management team
- VCN-01 in clinical trials
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High risk of regulatory setbacks
- Currently no revenue
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in oncolytic virus technology
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- AMGN
Competitive Landscape
Theriva Biologics faces competition from established pharmaceutical companies with greater resources. Its success depends on the differentiation and efficacy of its VCN-01 product candidate.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, as the company is focused on R&D and clinical development.
Future Projections: Future growth depends on the successful clinical development and commercialization of its product candidates. Analyst estimates vary widely due to the inherent uncertainties in the biotech industry.
Recent Initiatives: Recent initiatives include advancing VCN-01 through clinical trials and exploring partnerships for further development and commercialization.
Summary
Theriva Biologics is a high-risk, high-reward clinical-stage biotech company focused on oncolytic virus therapies. Its lead product candidate, VCN-01, is in clinical trials, and its future growth depends on successful development and commercialization. The company faces competition from larger pharmaceutical companies and requires significant funding to advance its pipeline. Financials and reverse stock splits show an at-risk situation. The company must watch for any unexpected threats to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotech industry is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theriva Biologics Inc.
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2006-12-18 | CEO, CFO, Treasurer, Corporate Secretary & Director Mr. Steven A. Shallcross CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://therivabio.com |
Full time employees 20 | Website https://therivabio.com | ||
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.